Navigation
-
Advaxis' John Rothman to Present Phase I Data at the World Vaccine Congress 2007
-
Cancer Vaccine Based on Listeria Aims to Stop and Eradicate Breast Cancers
-
Advaxis, Inc.'s CEO Leads $600,000 Bridge Financing Round
-
Advaxis Announces Completion of Patient Accrual in Lovaxin C Phase I/II Trial
-
Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
-
Two Leading Biotech Publications Report on Advaxis' Listeria Platform Technology
-
Recent HPV Findings by Centers for Disease Control and Prevention Validate Advaxis, Inc.'s Treatable Population
